From January 1, 2024 to March 31, 2024, the company has repurchased 2,966,000 shares, representing 0.2% for CNY 38.41 million. With this, the company has completed the repurchase of 7,023,100 shares, representing 0.48% for CNY 99.99 million under the buyback announced on November 14, 2023.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
17.53 CNY | -0.40% | +0.46% | +19.50% |
May. 13 | Huahai Pharmaceutical's Unit Gets Nod to Register Atomoxetine Hydrochloride Oral Solution | MT |
May. 02 | Huahai Pharmaceutical's Q1 Profit Jumps 57%, Income Up 21% | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.50% | 3.56B | |
+37.78% | 705B | |
+32.82% | 583B | |
-3.51% | 364B | |
+19.94% | 332B | |
+5.14% | 291B | |
+16.64% | 238B | |
-4.13% | 210B | |
+10.63% | 209B | |
+9.32% | 169B |
- Stock Market
- Equities
- 600521 Stock
- News Zhejiang Huahai Pharmaceutical Co., Ltd.
- Tranche Update on Zhejiang Huahai Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on November 14, 2023.